OBJECTIVE: To compare longitudinal trajectories of antiparkinsonian medication in STN-DBS treated patients to non-surgically treated control patients.
METHODS: We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex-distribution, and comorbidities.
RESULTS: In 74 DBS patients levodopa-equivalent daily dose (LEDD) were reduced by 33.9-56.0% in relation to the preoperative baseline over the 14-year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug-classes was observed for dopamine agonists.
CONCLUSIONS: In PD patients, chronic STN-DBS was associated with a lower LEDD compared with control patients over 14 years.
目的:比较STN-DBS治疗患者和非手术治疗对照组患者抗帕金森病药物的纵向轨迹。
方法:我们收集了1999年至2010年间接受丘脑下DBS治疗的PD患者和发病年龄和基线年龄相似的对照PD患者的抗帕金森病药物的回顾性信息。性别分布,和合并症。
结果:在74例DBS患者中,左旋多巴等效日剂量(LEDD)在14年的观察期内与术前基线相比减少了33.9-56.0%。在61名对照患者中,LEDDs在大约10年内增加,造成群体之间的显著分歧。观察到多巴胺激动剂在单一药物类别之间的最大差异。
结论:在PD患者中,与14年以上的对照组患者相比,慢性STN-DBS与较低的LEDD相关.